ETON 8-K 2026-11-05
Eton Pharmaceuticals, Inc. (ETON) 8-K dated 2026-11-05 — accession 0001710340-26-000006.
Eton Pharmaceuticals, Inc. (ETON) is a drug manufacturers - specialty & generic company listed on US.
ETON: Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported ETON revenue for 2025-12-31 was $80.0M. Net income was -$4.6M. Revenue was up 104.9% from 2024-12-31 to 2025-12-31. ETON currently screens at market cap $797.9M.
Not investment advice. The ETON SEC hub lists recent forms. The stock page is the research view.
- Diluted EPS
- $0.50
- Guidance
- guidance to more than $175 million, from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%,
Why it matters
- guidance to more than $175 million, from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%,